Fresenius Kabi AG
Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com
Latest From Fresenius Kabi AG
US Generics Market Continues To Seek Stability
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait
Pfizer has secured FDA approval for its adalimumab biosimilar under the name Abrilada, representing the agency’s 25th biosimilar approval overall. However, patent settlements around the Humira brand mean that Pfizer is not due to enter the market for four years.
US Generics Market Continues To Seek Stability
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Kabi Stretches Adalimumab Presence To Nine Countries
Having started to roll out its Idacio adalimumab biosimilar in Europe earlier this year, Fresenius Kabi is now marketing the Humira rival in nine countries.
Company Information
- Industry
-
Medical Devices
- Infusion Therapy Equipment and Supplies
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Fresenius SE & Co. KGaA
- Senior Management
- Rainer Baule, Chmn. & CEO
- Contact Info
-
Fresenius Kabi AG
Phone: (49) 6172 686 0
Else-Kröner-Straße 1
Bad Homburg , 61352
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice